Evidence map›Paper›PMID 33303811›Full record

ArticleScientific reports2020

Comprehensive analysis of liver and blood miRNA in precancerous conditions.

Tomohiro Umezu, Koichi Tsuneyama, Kohsuke Kanekura, Michiyo Hayakawa, Toshihito Tanahashi, Mitsuoki Kawano, Y-H Taguchi, Hidenori Toyoda, Akihiro Tamori, Masahiko Kuroda and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Tomohiro UmezuDepartment of Molecular Pathology, Tokyo Medical University, Shinjuku 6-1-1, Shinjuku-ku, Tokyo, 160-8402, Japan.
Koichi TsuneyamaDepartment of Pathology and Laboratory Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, 770-8503, Japan.
Kohsuke KanekuraDepartment of Molecular Pathology, Tokyo Medical University, Shinjuku 6-1-1, Shinjuku-ku, Tokyo, 160-8402, Japan.
Michiyo HayakawaDepartment of Pathology and Cell Regulation, Kyoto Prefectural University of Medicine, Kyoto, 602-0841, Japan.
Toshihito TanahashiTokushima Prefecture Naruto Hospital, Naruto, 772-8503, Japan.
Mitsuoki KawanoDepartment of Human Nutrition, Faculty of Contemporary Life Science, Chugokugakuen University, Okayama, 701-0197, Japan.
Y-H TaguchiDepartment of Physics, Chuo University, Tokyo, 112-8551, Japan.
Hidenori ToyodaDepartment of Gastroenterology, Ogaki Municipal Hospital, Ogaki, 503-8502, Japan.
Akihiro TamoriDepartment of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, 545-8585, Japan.
Masahiko KurodaDepartment of Molecular Pathology, Tokyo Medical University, Shinjuku 6-1-1, Shinjuku-ku, Tokyo, 160-8402, Japan.
Yoshiki MurakamiDepartment of Molecular Pathology, Tokyo Medical University, Shinjuku 6-1-1, Shinjuku-ku, Tokyo, 160-8402, Japan. yoshikim@tokyo-med.ac.jp.
Tokyo Medical University · JPChugoku Gakuen University · JPChuo University · JPKyoto Prefectural University of Medicine · JPNaruto, Tokushima Prefecture hospital · JPOgaki Municipal Hospital · JPOsaka City University · JPTokushima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Streptozotocin administration to mice (STZ-mice) induces type I diabetes and hepatocellular carcinoma (HCC). We attempted to elucidate the carcinogenic mechanism and the miRNA expression status in the liver and blood during the precancerous state. Serum and liver tissues were collected from STZ-mice and non-treated mice (CTL-mice) at 6, 10, and 12 W. The exosome enriched fraction extracted from serum was used. Hepatic histological examination and hepatic and exosomal miRNA expression analysis were serially performed using next-generation sequencing (NGS). Human miRNA expression analysis of chronic hepatitis liver tissue and exosomes, which were collected before starting the antiviral treatment, were also performed. No inflammation or fibrosis was found in the liver of CTL-mice during the observation period. In STZ-mice, regeneration and inflammation of hepatocytes was found at 6 W and nodules of atypical hepatocytes were found at 10 and 12 W. In the liver tissue, during 6-12 W, the expression levels of let-7f-5p, miR-143-3p, 148a-3p, 191-5p, 192-5p, 21a-5p, 22-3p, 26a-5p, and 92a-3p was significantly increased in STZ-mice, and anti-oncogenes of their target gene candidates were down-regulated. miR-122-5p was also significantly down-regulated in STZ-mice. Fifteen exosomal miRNAs were upregulated in STZ-mice. Six miRNAs (let-7f-5p, miR-10b-5p, 143-3p, 191-5p, 21a-5p, and 26a-5p) were upregulated, similarly to human HCC cases. From the precancerous state, aberrant expression of hepatic miRNAs has already occurred, and then, it can promote carcinogenesis. In exosomes, the expression pattern of common miRNAs between mice and humans before carcinogenesis was observed and can be expected to be developed as a cancer predictive marker.

Indexed as

AnimalsBiomarkers, TumorCarcinoma, HepatocellularExosomesHumansLiverLiver NeoplasmsMiceMicroRNAsPrecancerous ConditionsPredictive Value of TestsBiomarkers, TumorMicroRNAs

Identifiers

PMID33303811
PMCPMC7728755
OpenAlexW3110738097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.